Aardvark Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Aardvark Therapeutics, Inc. | AARD - NASDAQ |
$16.00-$18.00 | $16.00 | $15.18 | 5.88 million | 2/13/2025 |
| Morgan Stanley, BofA Securities, Cantor, RBC Capital | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2025-01-23 Terms Added 2025-02-06 | ||||||
Aardvark Therapeutics, Inc. Quote & Chart - Click for current quote - AARD
IPO Boutique aggregates information on public companies and private companies, such as "AARD" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Aardvark Therapeutics, Inc. (adapted from Aardvark Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "AARD" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.